Multiple Sclerosis | Access and Reimbursement | US | 2024

The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Ponvory, Briumvi, Tyruko) and nearest-to-launch emerging therapy (e.g., Glatiramer acetate Depot) have entered / will enter established drug classes, while novel Bruton’s tyrosine kinase (BTK) inhibitors will establish a new but potentially crowded class; in each case, demonstrating meaningful differentiation for payers and prescribers will be critical. Meanwhile, the debut of oral generics has introduced a new variable in formulary placement and physician choice, especially in the relapsing MS space. For developers bringing innovative or next-generation DMTs to market, understanding the current and future influence of clinical and economic metrics will be key.

Questions Answered

• What is the coverage status of key brands on commercial plans?
• How do DMT cost and payer restrictions influence clinical decision-making in MS today?
• How receptive are surveyed neurologists and payers to key novel and next-in-class agents?
• How is generics and biosimilar competition affecting coverage and prescribing in the MS market?
• What coverage and uptake are expected for future BTK inhibitors (e.g., Sanofi’s Tolebrutinib, Roche’s Fenebrutinib, and Novartis’s Remibrutinib)? What clinical and nonclinical differentiators would drive preferential use and coverage terms?

Product Description

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.

Markets covered: United States.

Primary research:

• Survey of 100 U.S. neurologists.
• Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Immunic Therapeutics, Merck, Novartis, Roche / Genentech, Sandoz, Sanofi, TG Therapeutics, Vanda, Viatris / Mapi Pharma.

Key drugs: Aubagio / teriflunomide, Briumvi, Bafiertam, Copaxone / glatiramer acetate, Gilenya / fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Tyruko, Vumerity, Zeposia, BTK inhibitors, Frexalimab, GA Depot, IMU-838.

Content highlights:

• Reimbursement and contracting.
• Access and prescribing.
• Opportunities and challenges for emerging therapies.
• Disease-specific special topics.